Back to Search Start Over

Supplementary Tables, Figures, References from Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells

Authors :
Phuong L. Doan
Stefanie Sarantopoulos
Neil L. Spector
David A. Rizzieri
Chang-Lung Lee
Sadhna O. Piryani
Angel Y.F. Kam
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

Supplemental Table 1. AML Patient demographics Supplemental Table 2. MDS Patient demographics Figure S1. ERBB2 is overexpressed and truncated in MDS and AML cells. Figure S2. Lapatinib effectively reduces levels of phospho-ERBB2 in MDS-L and K562 cells. Figure S3. ERBB2 inhibition with Lapatinib impairs MDS and AML cell proliferation. Figure S4. Afatinib and neratinib promotes leukemic cell death. Figure S5. ERBB2 inhibition with Lapatinib decreases MDS xenograft. Figure S6. Inhibition of MCL1 by AZD5991 enhances MDS-L cell death. Figure S7. Dual inhibition of ERBB2 and BCL-2 is synergistic to promote cancer death compared to monotherapy.

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....b838acd598d051e8ed29eaa8dfdd1edc
Full Text :
https://doi.org/10.1158/1541-7786.22526577